Literature DB >> 7098380

Kinetics and cardiac effects of propranolol in humans.

H R Ochs, E Grube, D J Greenblatt, M Knüchel, G Bodem.   

Abstract

Six healthy volunteers received single 20-mg intravenous (IV) and 80-mg oral doses of propranolol on two occasions in random sequence. Serum propranolol concentrations were determined by gas chromatography in multiple samples drawn during 24 h after each dose. Mean (+/- SE) kinetic variables for IV propranolol were: elimination half-life (t 1/2 beta), 5.3 (+/- 0.6) h; volume of distribution, 2.3 (+/- 0.3) l/kg; total clearance, 4.9 (+/- 0.3) ml/min/kg; predicted extraction ratio, 0.23 (+/- 0.02). After single oral doses, t 1/2 beta (3.8 +/- 0.2 h) tended to be smaller than after the IV dose, and actual systemic availability (0.60 +/- 0.07) was less than that based on the predicted extraction ratio. During multiple oral dosage (80 mg every 12 h), observed steady state serum levels (47 +/- 5 ng/ml) tended to be less than those predicted based on the single oral dose (61 +/- 5 ng/ml), thus providing no evidence for reduced propranolol clearance at steady-state. Echocardiographic measurements of left ventricular performance (posterior wall velocity, diastolic dimensions) made during the single-dose oral study indicated significant impairment of function; impairment was maximal at 3 h post-dosage, and corresponded to the time of the peak serum propranolol concentration (341 ng/ml).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7098380     DOI: 10.1007/BF01756098

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  20 in total

Review 1.  Predicting steady state serum concentrations of drugs.

Authors:  D J Greenblatt
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

2.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Effects of propranolol on left ventricular function in normal men.

Authors:  S Port; F R Cobb; R H Jones
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

4.  Biological determinants of propranolol disposition in man.

Authors:  D M Kornhauser; A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

Review 5.  Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Drugs       Date:  1974       Impact factor: 9.546

Review 6.  Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.

Authors:  D G Shand
Journal:  Drugs       Date:  1974       Impact factor: 9.546

7.  Effects of oral propranolol on left ventricular size and performance during exercise and acute pressure loading.

Authors:  M H Crawford; J Lindenfeld; R A O'Rourke
Journal:  Circulation       Date:  1980-03       Impact factor: 29.690

8.  Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans.

Authors:  H R Ochs; E Grube; D J Greenblatt; E Woo; G Bodem
Journal:  Am Heart J       Date:  1980-04       Impact factor: 4.749

9.  The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men.

Authors:  W F Cathcart-Rake; J E Coker; F L Atkins; D H Huffman; K M Hassanein; D D Shen; D L Azarnoff
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

10.  Effects of propranolol on left ventricular wall movement in patients with ischaemic heart disease.

Authors:  H von Bibra; D G Gibson; K Nityanandan
Journal:  Br Heart J       Date:  1980-03
View more
  1 in total

1.  Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Authors:  H R Ochs; P Hajdú; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1986-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.